ERBB2 and breast carcinoma: Moreover, the combination of trastuzumab and CH12 could synergistically inhibit the growth of EGFRvIII+HER2+ breast cancer via attenuating phosphorylation ERK and AKT more effectively and reversing STAT3 feedback activation.